NCT04903184View on ClinicalTrials.gov

Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers

PHASE2CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

November 11, 2021

Study Completion Date

November 11, 2021

Conditions
Covid-19
Interventions
BIOLOGICAL

RUTI® vaccine

Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.

BIOLOGICAL

Placebo

Physiological serum, 0.9% NaCl, will be used as a placebo.

Trial Locations (6)

Unknown

Hospital General de Agudos Dr. Ignacio Pirovano, Buenos Aires

Hospital Italiano de Buenos Aires, Buenos Aires

Hospital General, Mendoza

Hospital José Néstor Lencinas, Mendoza

Hospital de Clínicas Presidente Dr. Nicolás Avellaneda, San Miguel de Tucumán

"Hospital Materno Infantil Dr. Héctor Quintana", San Salvador de Jujuy

All Listed Sponsors
lead

RUTI Immunotherapeutics S.L.

INDUSTRY

NCT04903184 - Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers | Biotech Hunter | Biotech Hunter